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Summary
Background—Psychotherapy is not routinely recommended for in ulcerative colitis (UC). Gut-
directed hypnotherapy (HYP) has been linked to improved function in the gastrointestinal tract 
and may operate through immune-mediated pathways in chronic diseases.
Aims—To determine the feasibility and acceptability of hypnotherapy and estimate the impact of 
hypnotherapy on clinical remission status over a 1 year period in patients with an historical flare 
rate of 1.3 times per year.
Methods—54 patients were randomized at a single site to 7 sessions of gut-directed 
hypnotherapy (N = 26) or attention control (CON; N = 29) and followed for 1 year. The primary 
outcome was the proportion of participants in each condition that had remained clinically 
asymptomatic (clinical remission) through 52 weeks post-treatment.
Results—One-way ANOVA comparing hypnotherapy and control subjects on number of days to 
clinical relapse favored the hypnotherapy condition [F = 4.8 (1, 48), p = .03] by 78 days. Chi 
square analysis comparing the groups on proportion maintaining remission at 1 year was also 
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significant [X2(1) = 3.9, p = .04], with 68% of hypnotherapy and 40% of control patients 
maintaining remission for 1 year. There were no significant differences between groups over time 
in quality of life, medication adherence, perceived stress or psychological factors.
Conclusions—This is the first prospective study that has demonstrated a significant effect of a 
psychological intervention on prolonging clinical remission in patients with quiescent UC.
Clinical Trial # NCT00798642
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Introduction
Ulcerative colitis affects approximately 220 per 100,000 patients in the United States 1,2 and 
is associated with painful and unpredictable symptoms, undesirable psychosocial 
consequences3 and disability, particularly during periods of disease flare 4–7. Medical 
treatment is focused on prolonging remission and reducing exposure to environmental 
triggers of flare8. Psychosocial research in UC has been limited to survey studies 
characterizing co-morbid anxiety or depression in the setting of disease 9 or cross-sectional 
studies linking stressful experiences to the onset of disease flares10,11. However, the 
prevalence of psychological disorders in patients with UC mirrors that of the general 
population, particularly during quiescent disease states 12,13, and thus psychotherapy is not 
routinely recommended14.
Hypnotherapy, one of the first psychological therapies to be implemented in medical 
populations, has been linked to positive outcomes in a number of chronic diseases such as 
cancer 15–17, rheumatoid arthritis18, HIV19,20, fibromyalgia21,22 and chronic pain 23,24. 
Mechanistic studies suggest that hypnotherapy can have positive effects on immune 
parameters, with data supporting the effects of hypnotherapy on T-cell expression of 
interferon-gamma and interleukin-225, increases in secretory immunoglobulin-A and 
neutrophil adherence 26 and reductions in inflammatory markers such as erythrocyte 
sedimentation rate, c-reactive protein and leukocyte activity 18. Hypnotherapy used in 
inpatient medical settings has been associated with shorter length of hospital stays, 
decreased need for pain medication27,28, more rapid recovery from surgery 29 and faster 
wound healing 30–32.
Gut-directed hypnotherapy is a form of medical hypnosis that draws upon metaphors and 
delivers post-hypnotic suggestions specific to the improved health and function of the 
gastrointestinal tract. Hypnotherapy has demonstrated efficacy in several gastrointestinal 
disorders [see Palsson, 2010 33 for a review], with treatment gains maintained up to 5 
years 34. Gut-directed hypnotherapy is well-tolerated and effective in irritable bowel 
syndrome 34–36, functional dyspepsia37,38, non-cardiac chest pain 39, delayed gastric 
emptying40 and relapse prevention for duodenal ulcer41.
Limited data are available on the use of gut-directed hypnotherapy in inflammatory bowel 
diseases, with most research in this area limited to small, uncontrolled case series 42–46. One 
Keefer et al. Page 2






















particularly compelling study demonstrated that patients with active UC who underwent a 
single session of gut-directed hypnotherapy reduced mucosal release of substance P, 
histamine, and interleukin-13 and serum levels of interleukin-6 46, suggesting that 
hypnotherapy could have a disease-modifying impact on UC. We have previously reported 
on the preliminary findings from the Ulcerative Colitis Relapse Prevention Trial (UCRPT), 
an NIH-funded randomized controlled trial comparing gut-directed hypnotherapy to a time 
and attention control group in quiescent UC in which a 7-session gut-directed hypnotherapy 
program demonstrated improvement in health related quality of life, including reduction of 
bowel and systemic UC symptoms (IBDQ) and increased disease-specific self-efficacy 
immediately post-treatment and at 3 month follow-up 47.
UCRPT completed data acquisition in April, 2012 and we now report the results of our 
primary scientific question—can participation in a brief gut-directed hypnotherapy program 
prolong clinical remission among patients with quiescent UC? Our hypothesis was that 
hypnotherapy would be superior to control on two endpoints—1. the proportion of patients 
at 52 weeks who were still clinically asymptomatic and 2. number of days to first relapse.
Materials and Methods
Study Design
UCRPT was a prospective, single site randomized clinical trial comparing gut-directed 
hypnotherapy (HYP) against an active control condition (CON) on the primary outcome 
variable, which was the proportion of UC patients who remained clinically asymptomatic 
(no rectal bleeding, no diarrhea/ urgency or requirements to increase medication) through 1 
year follow-up. Repeated assessments of disease status (patient and physician), self-efficacy 
and quality of life were administered at baseline, 2 weeks post treatment, 20 weeks, 36 
weeks and 52 weeks post-treatment. This clinical trial was registered with 
www.clinicaltrials.gov/NCT00798642.
Participants
Male and female patients (ages 18 to 70), who were in remission, with endoscopy confirmed 
mild or moderately severe ulcerative colitis were invited to participate. Remission at the 
time of enrollment was operationally defined by a Mayo Score < 2 with no subscale > 1, and 
no rectal bleeding in last 2 weeks. We included only those patients who had a self-reported 
flare rate of > 1 per year and a documented disease flare within the past 1.5 years to enhance 
the opportunity to observe differences between groups over the course of a 1-year trial. As 
such, we expected to see primarily left-sided ulcerative colitis and some pancolitis with 
significant fewer patients with proctitis qualifying. Patients were required to be on a stable 
dose of maintenance medication (i.e. mesalamine or sulfasalazine) for at least one month 
prior to enrollment and could not have taken oral steroids within the past 30 days or topical 
steroids within the past 7 days. Exclusion criteria included any markers of active disease, a 
history of severe/fulminant UC, and other gastrointestinal disorders that could explain 
symptoms (e.g. Crohn’s disease, indeterminate colitis, short-bowel syndrome, renal/hepatic 
disease, Clostridium difficile infection, irritable bowel syndrome), pregnancy or intention to 
become pregnant in the next year, smoking cessation within the past 30 days, a prior history 
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with hypnotherapy as well as any of the common contraindications for hypnotherapy 48. We 
based sample size calculations on our previous research in this area—50 participants spread 
across two conditions is minimally acceptable (80% power) to detect an OR of 3.8 47,49.
Interventions
Both interventions were standardized and conducted on an individual, outpatient basis at a 
tertiary clinic in an academic medical center. Gut-directed hypnotherapy (HYP) is a 7-
session standardized treatment protocol delivered by 1 of 2 trained health psychologists (LK, 
JLK) in weekly, 40-minute sessions (Figure 2 for sample hypnotic suggestion). Sessions 
were fully scripted to ensure uniformity across therapists. Patients were provided a self-
hypnosis audio recording to practice outside of clinic 5 times per week during the study and 
then as they chose through follow-up 47. The control condition (CON) consisted of non-
directive discussion about UC and “the mind-body connection” with a separate post- 
doctoral fellow (MK). The therapist avoided any in-depth discussions of hypnotherapy or 
relaxation techniques to ensure difference from the experimental condition. Notably, the 
control treatment was not inert—participants were able to ask questions around disease self-
management of their therapist, and the therapist would point participants towards up-to-date 
information on behavioral self-management of IBD without directly encouraging behavior 
change. This treatment was previously validated as a credible intervention that controlled for 
time and clinical attention. Hypnotherapists were randomized on a 2:1 ratio (JLK:LK). 
Randomization allocation software was provided by the statistician (ZM) and the study 
coordinator enrolled and assigned participants to treatment. While blinding of the therapists 
or participants to the intervention was not possible, participants were blinded to study 
hypothesis and gastroenterologists were blinded to the treatment the participant’s received 
(HYP or CON). Participants were told that the goal of the study was to determine if 
behavioral therapies are an effective complementary therapy for IBD and that they would be 
assigned to one of two therapies: gut-directed hypnotherapy or a mind-body therapy aimed 
at identifying the impact of UC on the psyche and vice versa.
To ensure participants were blind to hypothesis, we administered the 10 point Expectancy 
and Credibility Questionnaire (1 not credible, 10 completely credible) after session 1. The 
mean score for the HYP group was 7.5 (0.9; 6–9) and the experimental group was 7.1 (1.5; 
5–9) demonstrating that each therapy was presented in an engaging and credible manner. 
We used separate therapists for the two conditions to reduce the effect of therapist 
allegiance, or the tendency for a therapist to unknowingly “water down” a treatment they do 
not necessarily believe is effective, on outcome 50. To further reduce the potential bias of 
not being able to blind participants or providers, all follow-up assessments were done online 
immediately prior to the patient’s “booster session” with the therapist. We also asked the 
patients not to share with their physicians the type of treatment they received until the end of 
the trial so as not to influence expectancy.
Measurement: Disease State
The primary outcome measure was the proportion of participants in each treatment group 
that were still in remission at 52 weeks post treatment. We used several subjective markers 
of flare given the absence of endoscopy:
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Baseline Sociodemographic and Clinical Information—Participants were asked to 
report several demographic and illness-related variables including disease duration, 
medication regimen, smoking, CAM use and medical history.
Daily Symptom Diaries—Participants completed an online time and date stamped 
standard symptom diary daily using a secure, password protected website during the 2-week 
baseline period and throughout treatment. The diaries asked patients to report on the 
presence and severity of rectal bleeding [referring to the most severe episode of the day on a 
scale of 0 (mild) to 3 (severe)], the number of stools during the day and the presence and 
severity of abdominal pain or discomfort (same scale 0–3) and general well-being [0 
(generally well) to 3 (poor)]. The diary was also re-assigned in 2-week periods prior to each 
repeated assessment interval to confirm remission status.
Flare Worksheet—Participants were instructed to complete this form at the first sign of a 
flare regardless of whether they were currently in one of the 2 week assessment intervals for 
UCRPT. The form was accessible online and asked participants to identify the date they first 
noticed symptoms, note the presence and frequency of rectal bleeding, average # of bowel 
movements per day since start of flare, average rating of abdominal pain since start of flare, 
general well-being and free text describing the situation. When completed, an alert was 
triggered to the study coordinator who was able to follow-up for additional details.
Modified Mayo Score—The Mayo Scoring System for the Assessment of UC activity is a 
12-point scale that reflects the physician’s clinical opinion of disease activity at each 
assessment interval. It was modified in this Phase I/II a study to exclude endoscopy results. 
This decision was based on factor analysis which revealed that other items included in 
disease activity indices (rectal bleeding, stool frequency/urgency) made the histological 
findings obtained on endoscopy redundant, with endoscopy accounting for less than 1% of 
the variance in predicting disease activity scores 51.
Inflammatory Bowel Disease Questionnaire (IBDQ)52—Participants completed the 
32-item version of the well- validated questionnaire to assess disease severity and quality of 
life in IBD, yielding four subscale scores: bowel health, systemic health, emotional 
functioning, and social functioning.
Morisky Medication Adherence Scale 53—Non-adherence to medication was assessed 
with a validated, 4-item questionnaire and allowed us to track adherence in the study to 
control for the effects of adherence to maintenance medications on relapse.
Measurement: Psychological questionnaires
Psychiatric comorbidity was assessed during the intake interview and participants with a 
psychiatric diagnosis (e.g. depression, bipolar disorder, panic disorder) were not included in 
this trial in order to maintain as much homogeneity as possible and reduce the possibility 
that the treatment worked through change in psychiatric symptoms.
Inflammatory Bowel Disease Self-Efficacy Scale (IBD-SES)—Drawn from social-
cognitive theory, self-efficacy is an individual’s personal beliefs about their ability to engage 
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in a certain behavior/set of behaviors and has been linked to healthy outcomes in a host of 
chronic diseases. Disease-specific self-efficacy reflects a person’s individual belief in his/her 
ability to manage IBD. Participants completed a 29-item validated disease-specific self-
efficacy measure54 with 4 subscales: managing stress and emotions, managing medical care, 
managing symptoms and disease, and maintaining remission.
Perceived Stress Questionnaire-Recent (PSQ)55—The PSQ-Recent is a 30-item 
validated measure of stress in the past month across 7 factors: harassment, overload, 
irritability, lack of joy, fatigue, worries, and tension. Items are rated on a 4-point Likert scale 
from “almost never” to “usually.” Higher scores suggest greater perceived stress. Norms 
have been previously reported in IBD 56.
Short Form 12 Health Survey Version 2 (SF-12v2)57—The SF-12v2 includes 12 
items from the Short-Form 36 Health Survey58 and yields a physical and mental composite 
score. Lower scores correspond with poorer general health-related quality of life.
Determination of Flare
Conservative estimates of flare occurrences were used. Patients were considered to have had 
a disease flare if any of the following were met: 1) patient completed the flare worksheet (N 
= 15), 2) Modified Mayo Score >2 or subscale was >1 at time of an assessment or self-
reported flare (N = 10); 3) patient self-reported a flare as rectal bleeding > 2 days with no 
other symptoms between assessment periods (N = 5); or 4) a patient’s therapy was escalated 
to include oral or topical steroids at any point in the 12 months or a new class of medications 
was added (N = 8). Once a flare occurred, we recorded the date it was first reported/
described to quantify the total number of days between study enrollment and time of flare. If 
a flare was not reported during the 12 month follow-up period and if we were unable to 
quantify time to the first flare, we recorded 366 days (1 year + 1 day) to flare (censored).
Maintenance of Remission
We defined continued clinical remission at 52 weeks as the absence of flare (defined above) 
during the 1 year follow-up phase. While there has been recent emphasis on the use of 
mucosal healing as the “gold standard” determinant of remission, the study was designed 
during a period of time where patient-centered reports of clinical remission were of similar 
utility to endoscopic indices 51,59. Indeed, Higgins et al suggested that unless a patient 
considers him/herself to be in remission, s/he is still likely to experience impairment, poor 
quality of life and high health use. Thus, the participant or his/her physician could not have 
reported a flare, defined above, at any of the previous follow-ups, or during the interval 
between week 36 and week 52. Participants were categorized at the 52 week follow- up 
according to the primary outcome variable: continued remission at week 52 (yes/no).
Statistical Analysis
Statistical analyses were completed using SPSS 20.0 for Windows (SPSS Inc., Chicago IL). 
ANOVA and chi-square tests were performed on baseline demographic and disease 
variables. There were no dropouts during active treatment in either condition, so intent-to-
treat procedures were unnecessary. When possible, a worst case carried forward approach 
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was employed for missing data. For example, if the patient did not have data at 1 year, they 
were assumed to have flared during the 52 week trial period. This approach left us with 3 
participants whose data was too unreliable to include in the analysis and 1 participant who 
withdrew consent. A Cox proportional hazards model was used to assess differences in days 
to flare for subjects in HYP versus CON. A one-way analysis of variance (ANOVA) test 
was performed to determine differences between the 2 groups on number of days to flare. 
Chi-square test was used to evaluate differences between groups in the proportion of 
individuals who had flared by one year. Multivariate analyses of variance were performed to 
determine changes in psychological questionnaire data over time [baseline, post-treatment, 
20 weeks, 36 weeks, 52 weeks].
Ethical considerations
The study was approved by the Institutional Review Board (IRB) of Northwestern 
University. All co-authors had access to the study data and have reviewed and approved the 
final manuscript.
Results
Participants were recruited over a 3-year period, from March, 2008 through Feb, 2011. 
There were no adverse effects in either treatment condition. See Figure 1 for CONSORT-NP 
statement. Of the 234 patients assessed for eligibility, 54 were randomized. Twenty 
participants were excluded from the 234 because of a contraindication to hypnotherapy (10 
for objection to hypnosis for religious purposes, 8 for unresolved trauma histories, 2 for 
history of mania/psychosis), another 20 were excluded for refusal to be randomized and 90 
were excluded due to active disease, steroid use, smoking or other medical exclusion 
criteria. Four patients were excluded because of psychiatric disorder. Forty-eight patients 
(90%) had left sided colitis of mild to moderate severity 6 had pancolitis. All patients were 
in clinical remission at the time of enrollment.
Fifty (50) patients (93%) were considered at 1 year follow-up (25 HYP, 25 CON). There 
were no differences between patients who followed up vs. failed to follow-up on 
demographic or clinical variables. The mean age of the sample was 38 years [range 18 to 65] 
with average disease duration of 9.5 years [range 1.5 to 35y].
Participants were 54% female, 86% white, non-Hispanic, 56% married and 75% with a 
college degree. One third reported a prior history of smoking but no participants had smoked 
within the last 2 years. Sixteen percent reported a positive family history of IBD. Seventy 
percent endorsed 5ASA use and 18% reported current azathiopurine use. None of the 
patients were currently using a biologic agent and 15% had a history of azathiopurine use. 
Only 2 participants reported no maintenance medication use. Sixty-four percent reported a 
history of oral steroid use in the last 1.5 years. Participants reported an average of 1.29 flares 
per year [range 1 to 5] with an average duration of flare of 6.3 weeks (SD=5.4), [range 1–
24]. The median number of days since last flare was 100 (19, 55–144). Baseline symptom 
diaries suggested that participants, who were all in remission, had an average of 3 bowel 
movements per day, mild daily abdominal pain/discomfort and excellent to good well-being. 
See Table 1.
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Overall baseline IBDQ score was 191 (SD=19.8), reinforcing remission status and a good 
disease-specific quality of life estimate.
Remission status by group
A one-way ANOVA comparing HYP and CON on number of days to relapse favored the 
HYP condition [F = 4.8 (1, 48), p = .03] by 78 days. Chi square analysis comparing the two 
groups on proportion who maintained remission at 1 year was also significant [X2(1) = 3.9, 
p = .04] with 68% of HYP patients and 40% of CON patients maintaining remission for 1 
year. See Table 2. A Cox proportional hazards model was used to assess differences in days 
to flare for subjects in HYP vs. CON. Overall, the risk of flare was estimated to be 2.11 
times greater in the CON vs HYP; however this result was not statistically significant (Wald 
Chi-square=2.87, p=.090).
Twenty-three patients flared during the study. There was one flare in a CON participant at 3 
month follow-up. By 6 month follow-up, 10 CON and 5 HYP had flared, and by 12 month 
follow-up 15 CON and 8 HYP had flared. Of those patients who flared, 15/23 (5 HYP, 10 
CON) reported it via the flare worksheet between assessment intervals and 10 of these were 
also confirmed by physician’s Modified Mayo Score (2 HYP, 8 CON). The additional 8 
participants who flared but did not complete a worksheet were identified through the 
medical record as requiring an escalation in therapeutic dose (3 HYP, 5 CON). Five/23 
participants who flared reported rectal bleeding >2 days as their sole indicator of flare (3 
HYP, 2 CON) but were not confirmed to have flared by the medical record or physician 
Mayo rating. Of those patients who flared, 22% (5) were stepped up from 5ASA only to 
azathioprine/mercaptopurine and 30% (7) had an escalation in 5ASA use. Nineteen percent 
(4) required oral steroid use at time of flare. There was no significant difference between 
groups in approach to flare. We were not powered to detect impact of hypnotherapy on flare 
characteristics.
There were no main effects or group X time interaction effects for any of the psychological 
questionnaires at 1 year follow-up F = 1.4(24, 16), p = .28 [Table 3a and b].
We also monitored adherence to recommended weekly, at-home practice and at 1-year 
follow-up, 52% of the HYP group was practicing self-HYP at least once per week.
Discussion
This is the first prospective study to our knowledge that has reported a demonstrable effect 
of a psychological intervention in prolonging remission in patients with quiescent UC. We 
found that hypnotherapy prolonged remission by a very conservative estimate of 
approximately 2.5 months, which is likely to be a clinically and subjectively significant 
benefit of the therapy considering that these patients had a pre-intervention annual flare rate 
of 1.3.
There are several strengths to this study. Participants were selected based on a flare rate of 
>1 per year and were “primed” for flare in that eligibility criteria required a documented 
disease flare within the past 18 months, making it more likely that they would flare during 
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the course of the 1 year follow-up period. However, the average flare rate still fell within 1–
2 per year. Thus, it is significant that 68% of the hypnotherapy group did not flare during the 
year post- treatment, contrary to the 40% seen in the time-attention control group. It is also 
important to note that the control group in this study was a one-on-one verbal intervention 
provided by a doctoral level therapist, not simply routine care. Comparing our intervention 
to wait-list (treatment as usual), while less rigorous, would likely have yielded more 
stunning results. Indeed, we have previously demonstrated that there is some immediate 
benefit on risk of flare derived from an active placebo condition 49. Furthermore, we did not 
detect a difference in treatment expectancy at baseline, suggesting that both treatments were 
presented with strong rationale.
That we were able to detect a difference between groups followed prospectively over 1 year 
with only 50 participants suggests that hypnotherapy is likely to be an effective 
complementary intervention in patients with mild to moderate UC, especially in contrast to 
no intervention, which is currently what patients receive in IBD centers. Furthermore, the 
majority of participants were practicing self-HYP on their own at one year, supporting its 
potential for sustainability and self-management therapeutic benefit even when a health 
psychologist is not readily available. Our results mirror IBD patient’s positive attitudes 
about the use of complementary and alternative therapies in IBD60. Finally, the fact that the 
hypnotherapy followed a standardized scripted protocol means that the same precise 
therapeutic components were delivered to all patients, and also that this intervention can 
easily be replicated, further tested and applied in clinical care by other groups.
Only 52% of the participants engaged in home practice of the hypnosis audio file, yet there 
was no relation between practice and no practice in terms of flare outcome. Previous 
research has shown lasting effects of gut-directed hypnotherapy (up to 7 years) on bowel 
symptoms, motility, abdominal pain and visceral hypersensitivity in functional 
gastrointestinal problems 33,61,62. Mechanisms proposed for these findings include cognitive 
change around the meaning of symptoms, improved motility and improved pain 
tolerance 62–64. Similarly, enduring effects of hypnotherapy have been attributed to learning 
that occurs occurring at the neurophysiological level; this has been linked to depth of 
trance 65 and type and ease of suggestion 66 and may be interesting for future research. Less 
is known about long-term benefits of hypnosis in chronic autoimmune conditions, but it is 
possible that increased awareness of body processes, improved self-care after participating 
in a program during remission and strengthening of the immune system more generally may 
explain some of the long-term effects of hypnotherapy noted in this study. Finally, recent 
support for the importance of brain-gut interactions in the clinical expression of IBD67 is 
highly compatible with our complementary approach to treatment—to the extent that gut-
directed hypnotherapy has been shown to modify brain-gut pathways and visceral 
hypersensitivity in functional gastrointestinal disorders such as irritable bowel syndrome68, 
it is possible that our intervention could impact IBD disease outcomes in a similar manner.
It is unlikely that patients participated in this study because of psychological distress—
indeed our patient population did not evidence any clinically significant depression, anxiety 
or stress at the time of study entry, which is consistent with other reports of psychological 
characteristics of patients with quiescent UC. The IBDQ, a well-recognized index of disease 
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specific quality of life 69 did not change with treatment in our group, likely because it is of 
limited value when patients are in remission at baseline70; differences in quality of life over 
time were not detectable, even in the group with a higher flare rate. Finally, rate of 
adherence to medication did not differ over time between the two groups, so adherence does 
not explain the difference in remission status over the course of 1 year.
We acknowledge a few important limitations to the study. First, we did not confirm flare and 
remission status endoscopically and instead relied on clinical symptoms, corroborated 
through daily symptom diaries, medical records, and patient and physician report. 
Inflammation has been shown to be present when clinical symptoms are absent in UC 71 and 
mucosal healing is gaining acceptance as an endpoint in clinical trials 72. We wish we had 
been able to use fecal calprotectin as a biomarker of flare or risk to flare for this study—at 
the time the NIH grant was awarded, this biomarker was still quite novel and expensive and 
not feasible for a pilot trial. Indeed, recent data suggests that high levels of perceived stress 
may contribute to higher symptom burden without altering fecal calprotectin levels, 
underscoring the importance of both objective and subjective markers of flare73. We cannot 
draw any conclusions on the mechanism through which hypnotherapy may have prolonged 
remission in this study, which highlights an interesting area for future research. Secondly, 
our patient population may not be representative of the typical UC patient seen in clinical 
practice—we are a tertiary care center with an integrated behavioral medicine and nutrition 
program and therefore our patients may be more motivated to participate in this type of 
research. An important next step in this line of inquiry would be a multi-center trial with a 
range of care settings and patient phenotypes. Finally, because the lead author served as a 
therapist in the hypnotherapy condition, it is possible that researcher allegiance impacted the 
outcome50. Unfortunately, at the time of the study, the lead author was also one of the few 
individuals qualified to provide the therapy. That said, the hypnotherapy was well-scripted 
and therefore it would have been difficult to impose considerable expectancy onto the 
individual patient. Future, multi-center trials could address this by training therapists.
If gut-directed hypnotherapy is effective in augmenting the time patient’s spend in clinical 
remission for even a portion of patients with UC, this would have marked clinical 
significance for the conventional management of IBD. This intervention may prove 
particularly useful for the large number of patients who have high rates of flare, difficulty 
obtaining remission, who become steroid dependent, or are otherwise resistant to 
maintenance medications.
Summary
This paper reports on an NIH funded RCT of gut-directed hypnotherapy in quiescent UC 
[NCT00798642]. The primary aims were to determine the feasibility and acceptability of 
hypnotherapy and estimate the impact of hypnotherapy on clinical remission status over a 1 
year period in patients with an historical flare rate of 1.2 times per year. This is the 1 year 
follow-up paper reporting on the impact of hypnotherapy on relapse. We found that patients 
receiving hypnotherapy were able to prolong clinical remission by 78 days, with 68% of 
HYP patients and 40% of CON patients maintaining remission for 1 year.
Keefer et al. Page 10























Supported by a grant from the National Institutes of Health R21AT0032004, clinical trial # NCT00798642
We also thank Monika Kwiatek, PhD for her assistance with the control condition, Edward Loftus, MD for his 
assistance with the choice of outcome measures, Rachel Lawton for her assistance with final chart review and all of 
the participants for their commitment to the project.
References
1. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s 
disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflammatory bowel 
diseases. 2007; 13:254–61. [PubMed: 17206702] 
2. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution 
of Crohn’s disease and ulcerative colitis in the United States. Clinical gastroenterology and 
hepatology : the official clinical practice journal of the American Gastroenterological Association. 
2007; 5:1424–9. [PubMed: 17904915] 
3. Waljee AK, Joyce JC, Wren PA, Khan TM, Higgins PD. Patient reported symptoms during an 
ulcerative colitis flare: a Qualitative Focus Group Study. European journal of gastroenterology & 
hepatology. 2009; 21:558–64. [PubMed: 19194304] 
4. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for 
inflammatory bowel disease based on the international classification of functioning, disability and 
health. Gut. 2012; 61:241–7. [PubMed: 21646246] 
5. Achleitner U, Coenen M, Colombel JF, Peyrin-Biroulet L, Sahakyan N, Cieza A. Identification of 
areas of functioning and disability addressed in inflammatory bowel disease-specific patient 
reported outcome measures. Journal of Crohn’s & colitis. 2012; 6:507–17.
6. Abraham BP, Sellin JH. Disability in inflammatory bowel disease. Gastroenterology clinics of 
North America. 2012; 41:429–41. [PubMed: 22500527] 
7. Reinisch W, Sandborn WJ, Bala M, et al. Response and remission are associated with improved 
quality of life, employment and disability status, hours worked, and productivity of patients with 
ulcerative colitis. Inflammatory bowel diseases. 2007; 13:1135–40. [PubMed: 17476675] 
8. Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M. A prospective population-based 
study of triggers of symptomatic flares in IBD. The American journal of gastroenterology. 2010; 
105:1994–2002. [PubMed: 20372115] 
9. Walker JR, Ediger JP, Graff LA, et al. The Manitoba IBD cohort study: a population-based study of 
the prevalence of lifetime and 12-month anxiety and mood disorders. The American journal of 
gastroenterology. 2008; 103:1989–97. [PubMed: 18796096] 
10. Keefer L, Keshavarzian A, Mutlu E. Reconsidering the methodology of “stress” research in 
inflammatory bowel disease. Journal of Crohns & Colitis. 2008; 2:193–201.
11. Maunder RG, Levenstein S. The role of stress in the development and clinical course of 
inflammatory bowel disease: epidemiological evidence. Current molecular medicine. 2008; 8:247–
52. [PubMed: 18537632] 
12. Rogala L, Miller N, Graff LA, et al. Population-based controlled study of social support, self-
perceived stress, activity and work issues, and access to health care in inflammatory bowel 
disease. Inflammatory bowel diseases. 2008; 14:526–35. [PubMed: 18183608] 
13. Graff LA, Walker JR, Clara I, et al. Stress coping, distress, and health perceptions in inflammatory 
bowel disease and community controls. The American journal of gastroenterology. 2009; 
104:2959–69. [PubMed: 19755973] 
14. von Wietersheim J, Kessler H. Psychotherapy with chronic inflammatory bowel disease patients: a 
review. Inflammatory bowel diseases. 2006; 12:1175–84. [PubMed: 17119392] 
15. Jensen MP, Gralow JR, Braden A, Gertz KJ, Fann JR, Syrjala KL. Hypnosis for symptom 
management in women with breast cancer: a pilot study. The International journal of clinical and 
experimental hypnosis. 2012; 60:135–59. [PubMed: 22443523] 
Keefer et al. Page 11






















16. Hudacek KD. A review of the effects of hypnosis on the immune system in breast cancer patients: 
a brief communication. The International journal of clinical and experimental hypnosis. 2007; 
55:411–25. [PubMed: 17786658] 
17. Sohl SJ, Stossel L, Schnur JB, Tatrow K, Gherman A, Montgomery GH. Intentions to use hypnosis 
to control the side effects of cancer and its treatment. The American journal of clinical hypnosis. 
2010; 53:93–100. [PubMed: 21049742] 
18. Horton-Hausknecht JR, Mitzdorf U, Melchart D. The effect of hypnosis therapy on the symptoms 
and disease activity in Rheumatoid Arthritis. Psychology & health. 2000; 14:1089–104. [PubMed: 
22175264] 
19. Rucklidge JJ, Saunders D. The efficacy of hypnosis in the treatment of pruritus in people with 
HIV/AIDS: a time- series analysis. The International journal of clinical and experimental 
hypnosis. 2002; 50:149–69. [PubMed: 11939276] 
20. Langenfeld MC, Cipani E, Borckardt JJ. Hypnosis for the control of HIV/AIDS-related pain. The 
International journal of clinical and experimental hypnosis. 2002; 50:170–88. [PubMed: 
11939277] 
21. Bernardy K, Fuber N, Klose P, Hauser W. Efficacy of hypnosis/guided imagery in fibromyalgia 
syndrome--a systematic review and meta-analysis of controlled trials. BMC musculoskeletal 
disorders. 2011; 12:133. [PubMed: 21676255] 
22. Alvarez-Nemegyei J, Negreros-Castillo A, Nuno-Gutierrez BL, Alvarez-Berzunza J, Alcocer-
Martinez LM. Ericksonian hypnosis in women with fibromyalgia syndrome. Revista medica del 
Instituto Mexicano del Seguro Social. 2007; 45:395–401. [PubMed: 17949578] 
23. Tan G, Fukui T, Jensen MP, Thornby J, Waldman KL. Hypnosis treatment for chronic low back 
pain. The International journal of clinical and experimental hypnosis. 2010; 58:53–68. [PubMed: 
20183738] 
24. Jensen MP. Hypnosis for chronic pain management: a new hope. Pain. 2009; 146:235–7. [PubMed: 
19596518] 
25. Wood GJ, Bughi S, Morrison J, Tanavoli S, Zadeh HH. Hypnosis, differential expression of 
cytokines by T-cell subsets, and the hypothalamo-pituitary-adrenal axis. The American journal of 
clinical hypnosis. 2003; 45:179–96. [PubMed: 12570090] 
26. Miller GE, Cohen S. Psychological interventions and the immune system: a meta-analytic review 
and critique. Health psychology : official journal of the Division of Health Psychology, American 
Psychological Association. 2001; 20:47–63.
27. Hypnosis before breast cancer surgery eases pain, cuts costs. Harvard women’s health watch. 2007; 
15:6.
28. Nash MR, Tasso A. The effectiveness of hypnosis in reducing pain and suffering among women 
with metastatic breast cancer and among women with temporomandibular disorder. The 
International journal of clinical and experimental hypnosis. 2010; 58:497–504. [PubMed: 
20799126] 
29. Lynch DF Jr. Empowering the patient: hypnosis in the management of cancer, surgical disease and 
chronic pain. The American journal of clinical hypnosis. 1999; 42:122–30. [PubMed: 10624023] 
30. Ginandes C, Brooks P, Sando W, Jones C, Aker J. Can medical hypnosis accelerate post-surgical 
wound healing? Results of a clinical trial The American journal of clinical hypnosis. 2003; 
45:333–51.
31. Kiecolt-Glaser H, Marucha PT, Atkinson C, Glaser R. Hypnosis as a modulator of cellular immune 
dysregulation during acute stress. Journal of consulting and clinical psychology. 2001; 69:674–82. 
[PubMed: 11550733] 
32. Kiecolt-Glaser JK, Glaser R, Strain EC, et al. Modulation of cellular immunity in medical students. 
Journal of behavioral medicine. 1986; 9:5–21. [PubMed: 2939253] 
33. Palsson OS. Hypnosis treatment for Gut Problems. European Gastroenterology and Hepatology 
Review. 2010; 6:42–6.
34. Tan G, Hammond DC, Joseph G. Hypnosis and irritable bowel syndrome: a review of efficacy and 
mechanism of action. The American journal of clinical hypnosis. 2005; 47:161–78. [PubMed: 
15754863] 
Keefer et al. Page 12






















35. Whitehead WE. Hypnosis for irritable bowel syndrome: the empirical evidence of therapeutic 
effects. The International journal of clinical and experimental hypnosis. 2006; 54:7–20. [PubMed: 
16316880] 
36. Palsson OS, Turner MJ, Johnson DA, Burnett CK, Whitehead WE. Hypnosis treatment for severe 
irritable bowel syndrome: investigation of mechanism and effects on symptoms. Digestive 
diseases and sciences. 2002; 47:2605–14. [PubMed: 12452403] 
37. Calvert EL, Houghton LA, Cooper P, Morris J, Whorwell PJ. Long-term improvement in 
functional dyspepsia using hypnotherapy. Gastroenterology. 2002; 123:1778–85. [PubMed: 
12454833] 
38. Sharma RL. Functional dyspepsia: At least recommend hypnotherapy. BMJ. 2008; 337:a1972. 
[PubMed: 18838430] 
39. Palsson OS, Whitehead WE. Hypnosis for non-cardiac chest pain. Gut. 2006; 55:1381–4. 
[PubMed: 16966696] 
40. Chiarioni G, Vantini I, De Iorio F, Benini L. Prokinetic effect of gut-oriented hypnosis on gastric 
emptying. Alimentary pharmacology & therapeutics. 2006; 23:1241–9. [PubMed: 16611286] 
41. Hypnotherapy for duodenal ulcer. Lancet. 1988; 2:159–60. [PubMed: 2899205] 
42. Shaoul R, Sukhotnik I, Mogilner J. Hypnosis as an adjuvant treatment for children with 
inflammatory bowel disease. Journal of developmental and behavioral pediatrics : JDBP. 2009; 
30:268. [PubMed: 19525722] 
43. Miller V, Whorwell PJ. Treatment of inflammatory bowel disease: a role for hypnotherapy? The 
International journal of clinical and experimental hypnosis. 2008; 56:306–17. [PubMed: 
18569141] 
44. Emami MH, Gholamrezaei A, Daneshgar H. Hypnotherapy as an adjuvant for the management of 
inflammatory bowel disease: a case report. The American journal of clinical hypnosis. 2009; 
51:255–62. [PubMed: 19216210] 
45. Keefer L, Keshavarzian A. Feasibility and acceptability of gut-directed hypnosis on inflammatory 
bowel disease: a brief communication. The International journal of clinical and experimental 
hypnosis. 2007; 55:457–66. [PubMed: 17786661] 
46. Mawdsley JE, Jenkins DG, Macey MG, Langmead L, Rampton DS. The effect of hypnosis on 
systemic and rectal mucosal measures of inflammation in ulcerative colitis. The American journal 
of gastroenterology. 2008; 103:1460–9. [PubMed: 18510607] 
47. Keefer L, Kiebles JL, Kwiatek MA, et al. The potential role of a self-management intervention for 
ulcerative colitis: a brief report from the ulcerative colitis hypnotherapy trial. Biol Res Nurs. 2012; 
14:71–7. [PubMed: 21362636] 
48. Hammond DC, Scheflin AW, Vermetten E. Informed consent and the standard of care in the 
practice of clinical hypnosis. The American journal of clinical hypnosis. 2001; 43:305–10. 
[PubMed: 11269633] 
49. Keefer L, Kiebles JL, Martinovich Z, Cohen E, Van Denburg A, Barrett TA. Behavioral 
interventions may prolong remission in patients with inflammatory bowel disease. Behaviour 
research and therapy. 2011; 49:145–50. [PubMed: 21256475] 
50. Munder T, Gerger H, Trelle S, Barth J. Testing the allegiance bias hypothesis: a meta-analysis. 
Psychotherapy research : journal of the Society for Psychotherapy Research. 2011; 21:670–84. 
[PubMed: 21797736] 
51. Higgins P, Schwartz M, Mapili J, Zimmerman EM. Is endoscopy necessary for the measurement of 
disease activity in ulcerative colitis? American Journal of Gastroenterology. 2005; 100:355–61. 
[PubMed: 15667493] 
52. Irvine EJ. Development and subsequent refinement of the inflammatory bowel disease 
questionnaire: a quality- of-life instrument for adult patients with inflammatory bowel disease. 
Journal of pediatric gastroenterology and nutrition. 1999; 28:S23–7. [PubMed: 10204520] 
53. Morisky D, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure 
of medication adherence. Medical care. 1986; 24:67–74. [PubMed: 3945130] 
54. Keefer L, Kiebles JL, Taft TH. The role of self-efficacy in inflammatory bowel disease 
management: preliminary validation of a disease-specific measure. Inflammatory bowel diseases. 
2011; 17:614–20. [PubMed: 20848516] 
Keefer et al. Page 13






















55. Levenstein S, Prantera C, Varvo V, Scribano ML, Berto E, Luzi C, Andreoli A. Development of 
the perceived stress questionnaire: A new tool for psychosomatic research. Journal of 
Psychosomatic Research. 1993; 37:19–32. [PubMed: 8421257] 
56. Levenstein S, Prantera C, Varvo V, Scriabno ML, Andreoli A, Luzi C, Arca M, Berto E, Milite G, 
Marcheggiano A. Stress and exacerbation in ulcerative colitis: A prospective study of patients 
enrolled in remission. American Journal of Gastroenterology. 2000; 95:1213–9. [PubMed: 
10811330] 
57. Ware, JE.; Kosinski, M.; Turner-Bowker, DM.; Gandek, B. Version 2 of the SF-12 Health Survey. 
Lincoln, RI: QualityMetric Incorporated; 2002. 
58. Ware, JE. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, 
New England Medical Center; 1993. 
59. Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined 
dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005; 
54:782–8. [PubMed: 15888785] 
60. Weizman AV, Ahn E, Thanabalan R, et al. Characterisation of complementary and alternative 
medicine use and its impact on medication adherence in inflammatory bowel disease. Alimentary 
pharmacology & therapeutics. 2012; 35:342–9. [PubMed: 22176478] 
61. Lindfors P, Unge P, Nyhlin H, et al. Long-term effects of hypnotherapy in patients with refractory 
irritable bowel syndrome. Scandinavian journal of gastroenterology. 2012; 47:414–20. [PubMed: 
22339617] 
62. Gonsalkorale WM, Miller V, Afzal A, Whorwell PJ. Long term benefits of hypnotherapy for 
irritable bowel syndrome. Gut. 2003; 52:1623–9. [PubMed: 14570733] 
63. Gonsalkorale WM, Toner BB, Whorwell PJ. Cognitive change in patients undergoing 
hypnotherapy for irritable bowel syndrome. Journal of psychosomatic research. 2004; 56:271–8. 
[PubMed: 15046962] 
64. Lea R, Houghton LA, Calvert EL, et al. Gut-focused hypnotherapy normalizes disordered rectal 
sensitivity in patients with irritable bowel syndrome. Alimentary pharmacology & therapeutics. 
2003; 17:635–42. [PubMed: 12641511] 
65. Berrigan LP, Kurtz RM, Stabile JP, Strube MJ. Durability of “posthypnotic suggestions” as a 
function of type of suggestion and trance depth. The International journal of clinical and 
experimental hypnosis. 1991; 39:24–38. [PubMed: 2001895] 
66. Trussell JE, Kurtz RM, Strube MJ. Durability of posthypnotic suggestions: type of suggestion and 
difficulty level. The American journal of clinical hypnosis. 1996; 39:37–47. [PubMed: 8917929] 
67. Bonaz BL, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. Gastroenterology. 
2013; 144:36– 49. [PubMed: 23063970] 
68. Lowen MB, Mayer EA, Sjoberg M, et al. Effect of hypnotherapy and educational intervention on 
brain response to visceral stimulus in the irritable bowel syndrome. Alimentary pharmacology & 
therapeutics. 2013; 37:1184–97. [PubMed: 23617618] 
69. Pallis AG, Mouzas IA, Vlachonikolis IG. The inflammatory bowel disease questionnaire: a review 
of its national validation studies. Inflammatory bowel diseases. 2004; 10:261–9. [PubMed: 
15290922] 
70. Huaman JW, Casellas F, Borruel N, et al. Cutoff values of the Inflammatory Bowel Disease 
Questionnaire to predict a normal health related quality of life. Journal of Crohn’s & colitis. 2010; 
4:637–41.
71. Baars JE, Nuij VJ, Oldenburg B, Kuipers EJ, van der Woude CJ. Majority of patients with 
inflammatory bowel disease in clinical remission have mucosal inflammation. Inflammatory 
bowel diseases. 2011
72. Dave M, Loftus EV Jr. Mucosal healing in inflammatory bowel disease-a true paradigm of 
success? Gastroenterology & hepatology. 2012; 8:29–38. [PubMed: 22347830] 
73. Sexton, K.; Bernstein, MT.; Walker, JR.; Graff, LA.; Miller, N.; Rogala, L.; Sargent, M.; 
Targownik, LE. Digestive Diseases Week. Orlando, FL: 2013. Perceived Stress Is Related to 
Symptom Burden, but Not Intestinal Inflammation, in Inflammatory Bowel Disease. 
Keefer et al. Page 14






















Figure 1. CONSORT Table for UCRPT
*1 dropout from CON during active treatment, 3 dropouts in CON a I occurred before 3 
month follow-up
+1 withdrew consent from HYP after active treatment (before 3 month followup)
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Example post-hypnotic suggestion from trial
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Table 1
Baseline and demographic characteristics of patients by condition.
Variable Hypnotherapy (N = 25) Attention Control (N = 25)
Gender 56% female (N = 14) 52% female (N = 13)
Race 84% white (N = 21) 88% white (N = 22)
Ethnicity 4% non-white Hispanic (N = 1) 4% non-white Hispanic (N = 1)
Marital status 48% married/life partner (N = 12) 64% married/life partner (N = 16)
Education 86% college degree or higher (N = 19) 68% college degree or higher (N = 17)
Mean (SD) Mean (SD)
Age 38.7 (11.8) 38.8 (12.1)
disease duration (y) 9.38 (7.95) 9.96 (6.73)
Disease extent 84% (N = 21) left sided colitis, 16% (N = 4) 
pancolitis
88% (N = 22) left sided colitis, 12% (N = 3) 
pancolitis
# BM/day 3.1 (.88) 3.3 (1.4)
Abdominal pain 1.3 (.43) 1.3 (.46)
Well-being 1.21 (.37) 1.2 (.54)
# flares per year 1.29 (.46) 1.29 (.46)
days since last flare 102.6 (20.8, 60–144) 99.2 (18.9, 55–136)
+5ASA use (current) 18 (72%) 17 (68%)
+ azathioprine/mercaptopurine use 
(current)
4 (16%) 5 (20%)
Duration of last flare (weeks) 6.1 (4.9, 1–16) 6.6 (6.0, 0.1–24)
+ History of smoking 8(32%) 7 (28%)
+ fam history of IBD 5 (20%) 3 (12%)
*
No differences between groups on any variables. All patients were in remission at the time of enrollment.
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Table 2
Changes in primary outcome measures at 1 year.
Variable Hypnotherapy (N = 25)
Mean (SD)
Attention Control (N = 25)
Mean (SD)
Test Statistic
Days to relapse 359.4 (145.9) 281.8 (100.5) t = 2.1 (1, 48), p = .03
Proportion still in remission at 1 year 17 (68%) 10 (40%) X2 (1) = 3.9, p = .04
IBDQ ↑2.3 (24.1) ↓7.9 (20.7) t (1,48) = .24, p = ns
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